Leslie Tari - Jul 1, 2021 Form 3 Insider Report for Cidara Therapeutics, Inc. (CDTX)

Role: Chief Scientific Officer
Signature: /s/ Leslie Tari
Stock symbol: CDTX
Transactions as of: Jul 1, 2021
Transactions value $: $0
Form type: 3
Date filed: 7/6/2021, 04:29 PM
Next filing: Jul 30, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	CDTX	Common Stock						2.55K	Jul 1, 2021	Direct
holding	CDTX	Common Stock						13.3K	Jul 1, 2021	By spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	CDTX	Stock Option (right to buy)							Jul 1, 2021	Common Stock	30.7K	$2.29	Direct	F1
holding	CDTX	Stock Option (right to buy)							Jul 1, 2021	Common Stock	49.7K	$2.45	Direct	F2
holding	CDTX	Stock Option (right to buy)							Jul 1, 2021	Common Stock	79.2K	$2.45	Direct	F1
holding	CDTX	Stock Option (right to buy)							Jul 1, 2021	Common Stock	85K	$1.98	Direct	F3
holding	CDTX	Stock Option (right to buy)							Jul 1, 2021	Common Stock	120K	$2.55	Direct	F4
holding	CDTX	Restricted Stock Unit							Jul 1, 2021	Common Stock	3.68K		Direct	F5, F6
holding	CDTX	Stock Option (right to buy)							Jul 1, 2021	Common Stock	918	$2.45	By spouse	F1
holding	CDTX	Stock Option (right to buy)							Jul 1, 2021	Common Stock	3.93K	$2.45	By spouse	F1
holding	CDTX	Stock Option (right to buy)							Jul 1, 2021	Common Stock	521	$1.98	By spouse	F1
holding	CDTX	Stock Option (right to buy)							Jul 1, 2021	Common Stock	104	$2.55	By spouse	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares are fully vested
F2	One-third (1/3) of the shares subject to the option vested on December 18, 2020 and the remainder vests and becomes exercisable in a series of twenty-four (24) successive equal monthly installments thereafter until fully vested on December 18, 2022.
F3	The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 19, 2020.
F4	The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 17, 2021.
F5	The shares shall vest upon the achievement of various clinical and corporate milestones.
F6	Restricted stock units convert into common stock on a one-for-one basis.